|premium|

OCGN Stock News and Price: Ocugen rips higher on WHO optimism

  • Ocugen has the rights to distribute Bharat Biotech's COVID-19 vaccine in the US and Canada.
  • The WHO is meeting on Wednesday to decide whether Covaxin can receive Emergency Use Listing.
  • OCGN stock is up more than 600% this year.

Ocugen (OCGN) opened up 8.1% to $15.11 on Tuesday, the day after it surged by 18.1% to $13.98. The company is a little-known biopharma player that studies gene therapies to cure blindness, but that is not the reason OCGN stock is soaring. 

OCGN News: Good news that might not help Ocugen either way

Instead, Ocugen owns the rights to sell Bharat Biotech’s COVID-19 vaccine in the US and Canada, and the World Health Organization (WHO) is meeting on Wednesday to determine whether to give the vaccine – Covaxin – an Emergency Use Listing (EUL) that would allow it to be purchased for use in more than 100 countries as part of the COVAX Facility. 

If Covaxin is approved, it will greatly benefit Bharat, but will it help Ocugen’s bottom line? The US and Canada are donors rather than beneficiaries of the COVAX Facility, which is an initiative of the Vaccines Alliance.

The more important test for OCGN stock is whether Canada approves its application to distribute there. Likewise, Ocugen is hoping to get the US Food & Drug Administration to approve its phase-3 study for Covaxin.

OCGN key statistics                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

Market Cap$2.8 billion
Price/EarningsN/A
Price/SalesN/A
Price/Book20.2
Enterprise Value$2.2 billion
Gross MarginN/A
Net Margin            

N/A

            
52-week high$18.77
52-week low$0.27
Short Interest28.7%
Average Wall Street Rating and Price TargetHold $8.88

 

OCGN Stock Chart: Sell the news

Trading as high as $778.20 near its debut in December 2014, Ocugen is a stock that has trended down for years and lost as much as 99% of value in the seven years since. It was trading for mere pennies in 2020 but is up more than 600% this year.

Still, OCGN has a penchant for volatile spikes that make retail traders love it. Just as fast though, these spikes typically diminish within a day or two. At Monday’s closing price of $13.98, the clear target is $16.20. This was the swing high from May 3. That spike was much lower than the February 8 spike that went as high as $18.77. The closing prices on those days were quite close – $15.68 and $15.81. This area may also act as resistance as some traders decide to bail.

FXStreet View: Sell the news. No matter which way the decision goes at the WHO advisory meeting on Wednesday, OCGN stock is likely to sell off as it has in the past. If you are holding on Tuesday, now is the time to book profits.

OCGN daily chart

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to PremiumSign In

Author

Clay Webster

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

More from Clay Webster
Share:

Editor's Picks

GBP/USD loses momentum, flirts with 1.3200

GBP/USD is struggling to maintain its positive bias on Thursday, retreating toward the 1.3200 region in response to the pick in the buying interest around the Greenback. That said, Cable remains under scrutiny as cautious market sentiment keeps investors focused on the US-Iran conflict and political effervescence in the UK.

EUR/USD trims gains, challenges 1.1400

EUR/USD now gives away part of its earlier advance, receding toward the 1.1400 contention zone on Thursday. Meanwhile, the pair’s recovery comes amid extra losses in the US Dollar, at the time when while investors continue to monitor developments in the Middle East and sentiment surrounding global technology stocks.

Gold remains bid and close to $4,100

Gold accelerates its recovery and approaches the key $4,000 mark per troy ounce at the end of the week, adding to Thursday’s advance. However, expectations for a hawkish Fed remain steady and keep the yellow metal’s potential upside contained.

Crypto Today: Bitcoin at $60,000, Ethereum at $1,500, and XRP at $1 face a make-or-break test

Bitcoin (BTC), Ethereum (ETH), and Ripple (XRP) are trading in the red on Friday after three consecutive days of losses, testing their respective make-or-break support levels.

Week ahead – NFP report to challenge Dollar strength and the hawkish Fed

Dollar strength dominates markets, as the hawkish Fed overshadows geopolitics and lower oil prices. NFP week could drive September Fed hike expectations and boost market volatility. The euro lacks fresh bullish catalysts, all eyes on the preliminary inflation report and the ECB Forum.

Regime change: Inside Kevin Warsh's first move to make the Fed unreadable on purpose

The rate did not move. That was the least interesting thing about Kevin Warsh's first meeting in charge of the Fed. The FOMC held its benchmark at 3.50%-3.75% for the fourth straight meeting, exactly as priced, and then the new chair used his first press conference to dismantle the machinery the market has leaned on for a decade.